EAP for convalescent plasma no longer enrolling; the FDA authorized emergency use.

Program Highlights

  • A new paper has been added, "Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors." See the publications page.

  • Sample program data entry forms have been added in the Physicians section. View the PDF.
  • A list of educational activities provided by the EAP team has been added in a new section. See the list.
  • Uscovidplasma.org included in national archive

    The Library of Congress has selected the USCOVIDplasma.org website for inclusion in the nation's historic Coronavirus Web Archive. Selection for the archive demonstrates the significant role of the EAP in the US response to the pandemic, and Mayo Clinic's leadership role. Access to the site will be available at the Library of Congress in Washington, D.C., and on the library's public access website as early as fall 2021.

  • Data analysis

    The EAP team continues to analyze data from the program and publish its findings, which were an important component of the scientific evidence considered by the U.S. Food and Drug Administration in the decision to issue an Emergency Use Authorization on August 23, 2020, to permit the use of convalescent plasma for treatment in hospitalized patients with COVID-19.

Historical EAP program participation

Participating locations and enrolled providers

  • Sites
  • Physicians
  • Patients
  • Infused